Samyang-LG Collaborate for mRNA Anticancer Drug Development

Samyang Holdings and LG Chem announced on the 20th that they have signed a strategic partnership agreement to apply Samyang Holdings' proprietary drug delivery technology for the development of messenger ribonucleic acid (mRNA)-based anticancer new drugs.

At the recent mRNA delivery technology transfer contract ceremony held at LG Science Park in Gangseo-gu, Seoul, Lee Young-jun, CEO of Samyang Holdings (left), and Son Ji-woong, head of LG Chem's Life Sciences Division, are posing for a commemorative photo.
[Photo by Samyang Holdings]

This contract is a non-exclusive technology transfer agreement, under which Samyang Holdings will provide LG Chem with the technology and related compositions of its self-developed mRNA delivery system, ‘NanoReady’. LG Chem plans to integrate this to discover innovative mRNA-based new drug substances that maximize anticancer efficacy. LG Chem will pay Samyang Holdings an upfront fee and milestone payments according to development stages.

mRNA is genetic material that carries information to produce specific proteins inside cells. To develop mRNA as a therapeutic agent, drug delivery technology that safely delivers mRNA into cells and efficiently facilitates protein expression is essential. Samyang Holdings emphasizes the high versatility of its proprietary drug delivery technology for NanoReady. By mixing LG Chem’s developed mRNA efficacy substances with pre-manufactured delivery compositions, the coupling process is simplified, which is expected to shorten new drug development periods and be effective for personalized therapies.

Samyang Holdings’ Biopharm Group, which has focused its capabilities on drug delivery systems (DDS) including drug delivery vehicles, is accelerating the development of various mRNA delivery systems not only for NanoReady but also for preventive vaccines and rare disease therapeutics. Additionally, they plan to develop various therapeutics through long-term selective mRNA delivery systems that overcome the limitations of existing mRNA delivery vehicles.

Lee Young-jun, CEO of Samyang Holdings, said, “LG Chem is a company with excellent new drug development capabilities and numerous new drug pipelines. We plan to further strengthen our cooperative relationship through this contract,” adding, “By combining the strengths of both companies, we will accelerate the development of innovative anticancer new drugs and contribute to improving the quality of life for patients suffering from cancer.” Son Ji-woong, head of LG Chem’s Life Sciences Division, also stated, “We will maximize the outcomes of our collaboration to present advanced mRNA anticancer new drugs to patients worldwide.”

This content was produced with the assistance of AI translation services.